Mankind Pharma net profit rises 21 percent to Rs 511 crore in Q2

The company had reported a net profit of Rs 422 crore in the July-September period of the last fiscal.

Revenue from operations rose to Rs 2,708 crore in the period under review from Rs 2,425 crore in the year-ago period, Mankind Pharma said in a regulatory filing.

“We continue to report steady performance with Revenue/ EBITDA and PAT growing by 12% / 15% and 21% YoY respectively. While the Pharma segment has grown at par with IPM (vs outperformance earlier) – due to delayed acute season, we expect to outperform IPM given strong chronic growth and uptick in season. Focus to increase our chronic share led to outperformance of 1.4x versus IPM Chronic growth in H1FY24," Mankind Pharma Vice Chairman & Managing Director Rajeev Juneja said.

"The past strategic choices in various aspects of our business are showing success, and we are confident in our ability to consistently surpass the industry growth in future," he further said.

Headquartered in Delhi, Mankind Pharma is an Indian pharmaceutical and healthcare products company. The Company has a significant presence in the domestic pharmaceuticals business across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, VMN and respiratory, among others. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. The company has 25 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products.